Physician profile
Earlene C Siebold
NPI 1134101157
$3,693.62
in general payments reported to CMS, 2019-2025
20 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $424 · 2021: $322 · 2022: $553 · 2023: $410 · 2024: $527 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $610.51 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $450.09 | 2019-2025 | Rocklatan, Hydrus Microstent, Simbrinza |
| Sun Pharmaceutical Industries INC. | $430.00 | 2019-2025 | Cequa |
| Allergan, INC. | $379.91 | 2019-2022 | |
| Abbvie INC. | $364.75 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Aerie Pharmaceuticals, INC. | $335.15 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $285.61 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $186.60 | 2022-2025 | Vyzulta, Infuse, Scoutpro Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.08 | 2019-2021 | |
| Oyster Point Pharma, INC. | $113.18 | 2022-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $95.01 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $92.23 | 2024-2025 | Iyuzeh |
| Amgen INC. | $60.46 | 2024-2025 | Tepezza |
| Omeros Corporation | $38.62 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $28.39 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $26.23 | 2025 | Myday Contact Lens |
| Ivantis, INC | $18.23 | 2020 | |
| Biotissue Holdings INC. | $17.20 | 2025 | |
| Eyevance Pharmaceuticals LLC | $13.03 | 2023 | Flarex |
| Kala Pharmaceuticals, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earlene Siebold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.